Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 76Polycystic Ovary Syndrome 3Neoplasms, Hormone-Dependent 3Neoplasm Metastasis 3Arthralgia 3Advanced Breast Cancer 3Osteoporosis 2Fractures, Bone 2Endometrial Neoplasms 2Carcinoma, Lobular 2Carcinoma, Intraductal, Noninfiltrating 2Carcinoma, Ductal, Breast 2Breast Diseases 2Breast Cancer Female 2Sexuality 1Sexual Dysfunctions, Psychological 1Neurotoxicity Syndromes 1Luminal B/HER2-negative Breast Cancer 1Leiomyoma 1Infertility 1Hot Flashes 1Hormone-receptor-positive Breast Cancer 1Hormone Receptor Positive Breast Carcinoma 1Hormone Receptor Positive Advanced Breast Cancer 1Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer 1HR+/HER2- Early Breast Cancer 1HR+/HER2+ Early Breast Cancer 1Fatigue 1Estrogen Receptor and/or Progesterone Receptor Positive 1Endometrial Stromal Tumors 1

Interventions

Acupuncture Therapy 10Gabapentin 7Venlafaxine Hydrochloride 5Tamoxifen 3Isoflavones 3Estrogens, Conjugated (USP) 3Bupivacaine 3liposomal amphotericin B 2fezolinetant 2black cohosh root extract 2Soybean Proteins 2Sodium Chloride 2Moxifloxacin 2Magnesium Oxide 2Hypnosis 2Control Groups 2Citalopram 2Caspofungin 2zopiclone 1oxybutynin 1bazedoxifene 1Zolpidem 1Vitamin B 6 1Vancomycin 1Therapeutics 1Testosterone 1Tazobactam 1Tablets 1Sugars 1Solifenacin Succinate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hot Flashes × Aromatase Inhibitors × Clear all
NCT06440967 2026-04-06

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

Astellas Pharma Inc

Phase 3 Active not recruiting
984 enrolled

Hot Flashes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡